DexComDXCM +1.18%90 Days Payable is 76.31 as of Mar. 2026, which is 8% above its 10-year median of 70.59. GuruFocus rates DXCM with a GF Score™ of 90/100 and a GF Value™ of $103.54 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 795 Medical Devices & Instruments companies, DexCom ranks better than 58.36% on this metric.
DexCom's average Accounts Payable for the
three
months ended in Mar. 2026 was $369 Mil. DexCom's Cost of Goods Sold for the
three
months ended in Mar. 2026 was $442 Mil.
Hence, DexCom's Days Payable for the
three
months ended in Mar. 2026 was 76.31.
The historical rank and industry rank for DexCom's Days Payable or its related term are showing as below:
DXCM'
s Days Payable Range Over the Past 10 Years
Min: 56.28 Med: 70.59 Max: 83.81
Current: 82.42
During the past 13 years, DexCom's highest Days Payable was 83.81. The lowest was 56.28. And the median was 70.59.
DXCM's Days Payable is ranked better than 58.36% of 795
companies
in the Medical Devices & Instruments industry
Industry Median: 67.87
vs DXCM: 82.42
DexCom's Days Payable
declined
from Mar. 2025 (79.34) to Mar. 2026 (76.31).
It may suggest that DexComaccelerated paying its suppliers.
DexCom Days Payable Related Terms
DexCom Days Payable Historical Data
* Premium members only.
The historical data trend for DexCom's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, DexCom's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
DexCom Days Payable vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, DexCom's Days Payable distribution charts can be found below:
* The bar in red indicates where DexCom's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
DexCom's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DexCom (DXCM) has a Days Payable of 76.31 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on DexCom and its competitors. This is near median its historical median of 70.59. Over the past decade, DexCom's Days Payable has ranged from 56.28 to 83.81. According to the industry distribution chart, DexCom ranks #331 out of 795 companies in the Medical Devices & Instruments industry, placing it in the top 41.6%.
Is DexCom's Days Payable too high?
DexCom's current Days Payable of 76.31 is near median its 10-year median of 70.59. Over the past 10 years, this metric has ranged from a low of 56.28 to a high of 83.81. The Medical Devices & Instruments industry median Days Payable is 67.87. DexCom's value of 76.31 is 12.4% above this industry median. Based on the distribution chart, DexCom ranks #331 out of 795 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, DexCom has a GF Score™ of 90/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does DexCom's Days Payable compare to GEHC and STE?
According to the Medical Devices & Instruments industry distribution chart, DexCom ranks #331 out of 795 companies for Days Payable. This puts DexCom in the upper half of its industry. The industry median Days Payable is 67.87. DexCom's value of 76.31 is 12.4% above this benchmark. Historically, DexCom's own Days Payable has ranged from 56.28 to 83.81 over the past decade. While the company's 10-year median is 70.59 vs. the industry median of 67.87, DexCom has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Devices & Instruments company?
The median Days Payable among Medical Devices & Instruments companies is 67.87, based on 795 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. DexCom's current Days Payable of 76.31 is 12.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on DexCom and its competitors. For the Medical Devices & Instruments industry, the median Days Payable is 67.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. DexCom's current Days Payable is 76.31, which is near median its own 10-year median of 70.59. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DexCom stock overvalued right now?
Based on GuruFocus' analysis, DexCom (DXCM) is currently considered Significantly Undervalued. The stock's GF Value™ is $103.54, compared to a current price of $69.75 — trading 32.6% below its estimated fair value. The current Days Payable is 76.31, which is near median its 10-year median of 70.59 and 12.4% above the Medical Devices & Instruments industry median of 67.87. DexCom's overall GF Score™ is 90/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For DexCom (DXCM), the current Days Payable is 76.31 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is DexCom (DXCM) Overvalued in 2026?
Based on GuruFocus' analysis, DexCom stock appears to be undervalued.
The current stock price of $69.75 is trading 32.6% below its estimated GF Value™ of $103.54.
GuruFocus considers DexCom to be Significantly Undervalued.
Key valuation signals for DXCM:
Days Payable: 76.31 (near median its 10-year median of 70.59)
GF Value™: $103.54 vs. price of $69.75 (32.6% below fair value)
Industry Position: 12.4% above the Medical Devices & Instruments median (#331 of 795)
No single metric tells the full story. See the DXCM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
DexCom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery. DexCom's CGMs are available through medical equipment distributors as well as retail pharmacies.
90GF Score
Get the complete analysis for DXCM
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DXCM has been successfully added to your 
